HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Aurelio Chaux Jack M. Matloff Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chaux, A. Articles by Matloff, J. M. Search for Related Content PubMed PubMed Citation Articles by Chaux, A. Articles by Matloff, J. M.

J Thorac Cardiovasc Surg 1998;115:604-614
© 1998 Mosby, Inc.

SURGERY FOR ACQUIRED HEART DISEASE

Perivascular Delivery Of A Nitric Oxide Donor Inhibits Neointimal Hyperplasia In Vein Grafts Implanted In The Arterial Circulation

Supported in part by the Western Cardiac Foundation, the Deutsch Family Foundation, and Norman and Georgette Bloom.

Read at the Twenty-third Annual Meeting of The Western ThoracicSurgical Association, Napa, Calif., June 25-28, 1997.

Received for publication July 8, 1997; revisions requested August 18, 1997; revisions received Sept. 18, 1997; accepted for publication Sept. 18, 1997. Address for reprints: Aurelio Chaux, MD, 10965 Savona Rd., LosAngeles, CA 90077.

Abstract

Objective: Nitric oxide has been reported to reduce intimal hyperplasia as a response to arterial injury. This study was designed to assess the possible effect of perivascular application of a nitric oxide donor on neointimal proliferation occurring in veins exposed to the dynamics of the arterial circulation in a hypercholesterolemic rabbit model.
Methods: Autologous jugular vein grafts were implanted in the carotid circulation of 20 hypercholesterolemic rabbits. A mixture of a biodegradable polymer and the nitric oxide donor, spermine/nitric oxide, which releases nitric oxide with a half-life of 39 minutes, was applied periadventitially at the time of implantation. Controls were veins bathed in saline solution, polymer alone, and polymer plus the carrier vehicle spermine without nitric oxide. Animals (n = 5 in each group) were put to death on day 28 for morphometric analysis, cell count, and immunohistochemical staining.
Results: Treatment with perivascular nitric oxide donor significantly decreased wall thickness (126 ± 24 µm vs 208 ± 45 µm, p = 0.0017) and area (124 ± 22 µm²/µm vs 211 ± 37 µm²/µm, p = 0.005). With the carrier vehicle spermine alone, there was a trend toward reduced intimal thickness, but the change was not statistically significant. In the grafts treated with nitric oxide donor, expression of insulin-like growth factor, fibroblast growth factor, thrombospondins, fibronectin, and tenascin was reduced.
Conclusion: The periadventitial delivery of nitric oxide donor produces a reduction of neointimal hyperplasia in veins implanted in the arterial circulation. The mechanism of action is not entirely clear, but the reduction cannot be explained on the basis of decreased cell proliferation alone. Other possibilities are modulation of protein synthesis of vascular smooth muscle cells and production of extracellular matrix components.

This article has been cited by other articles:

				S. S. Ahanchi, V. N. Varu, N. D. Tsihlis, J. Martinez, C. G. Pearce, M. R. Kapadia, Q. Jiang, J. E. Saavedra, L. K. Keefer, J. A. Hrabie, et al. Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2388 - H2398. [Abstract] [Full Text] [PDF]

				T. Schachner, G. Laufer, and J. Bonatti In vivo (animal) models of vein graft disease. Eur. J. Cardiothorac. Surg., September 1, 2006; 30(3): 451 - 463. [Abstract] [Full Text] [PDF]

				B. Kelly, M. Melhem, J. Zhang, G. Kasting, J. Li, M. Krishnamoorthy, S. Heffelfinger, S. Rudich, P. Desai, and P. Roy-Chaudhury Perivascular paclitaxel wraps block arteriovenous graft stenosis in a pig model Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2425 - 2431. [Abstract] [Full Text] [PDF]

				T. Schachner Pharmacologic inhibition of vein graft neointimal hyperplasia J. Thorac. Cardiovasc. Surg., May 1, 2006; 131(5): 1065 - 1072. [Abstract] [Full Text] [PDF]

				T. Yamaoka, Y. Yonemitsu, K. Komori, H. Baba, T. Matsumoto, T. Onohara, and Y. Maehara Ex vivo electroporation as a potent new strategy for nonviral gene transfer into autologous vein grafts Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1865 - H1872. [Abstract] [Full Text] [PDF]

				A. Chaux Preservation of saphenous vein endothelium Ann. Thorac. Surg., April 1, 2004; 77(4): 1505 - 1505. [Full Text] [PDF]

				Y. S. Do, E. Y. Kao, F. Ganaha, H. Minamiguchi, K. Sugimoto, J. Lee, C. J. Elkins, P. G. Amabile, M. D. Kuo, D. S. Wang, et al. In-Stent Restenosis Limitation with Stent-based Controlled-Release Nitric Oxide: Initial Results in Rabbits Radiology, February 1, 2004; 230(2): 377 - 382. [Abstract] [Full Text] [PDF]

				S. Kaul, B. Cercek, J. Rengstrom, X.-P. Xu, M. D. Molloy, P. Dimayuga, A. K. Parikh, M. C. Fishbein, J. Nilsson, T. B. Rajavashisth, et al. Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: role of nuclear factor-kappaB J. Am. Coll. Cardiol., February 1, 2000; 35(2): 493 - 501. [Abstract] [Full Text] [PDF]